Topic 36

ace2 sars cov angiotensin converting entry covid receptor spike 19 coronavirus enzyme respiratory infection viral virus severe syndrome tmprss2 rbd binding pandemic acute host 2019 protein human domain lung cells disease protease caused affinity epithelial interaction cell surface glycoprotein viruses expression fusion hace2 patients susceptibility serine expressed microbiology may s1 residues epithelium transmission airway its coronaviruses infected binds health therapeutic spread alveolar infectivity cov2 pseudotyped bind global tropism potential block pathogenesis symptoms antibody receptors infections replication cleavage express enter agent enters neutralizing interface has simulations public furin antibodies tissues s2 lungs expressing priming pseudovirus severity vaccines susceptible target structural inhibit

319 items. Top items listed below.

Many bat species are not potential hosts of SARS-CoV and SARS-CoV-2: Evidence from ACE2 receptor usage 36 1

Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement 36 24 1

SARS-CoV-2 manipulates the SR-B1-mediated HDL uptake pathway for its entry 36 1

Computational analysis on the ACE2-derived peptides for neutralizing the ACE2 binding to the spike protein of SARS-CoV-2 36 1

Genetic analysis of the novel SARS-CoV-2 host receptor TMPRSS2 in different populations. 36 1

Interaction of human ACE2 to membrane-bound SARS-CoV-1 and SARS-CoV-2 S glycoproteins 36 1

Monoclonal antibodies for the S2 subunit of spike of SARS-CoV cross-react with the newly-emerged SARS-CoV-2 36 1

Impact of Thiol-Disulfide Balance on the Binding of Covid-19 Spike Protein with Angiotensin Converting Enzyme 2 Receptor 36 1

Genetic variability in the expression of the SARS-CoV-2 host cell entry factors across populations 36 1

Oral epithelial expression of angiotensin converting enzyme-2: Implications for COVID-19 diagnosis and prognosis. 36 1

Naturally mutated spike proteins of SARS-CoV-2 variants show differential levels of cell entry 36 1

Bcr-Abl tyrosine kinase inhibitor imatinib as a potential drug for COVID-19 36 1

Increasing Host Cellular Receptor--Angiotensin-Converting Enzyme 2 (ACE2) Expression by Coronavirus may Facilitate 2019-nCoV Infection 36 1

Structural investigation of ACE2 dependent disassembly of the trimeric SARS-CoV-2 Spike glycoprotein 36 1

Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies 36 24 1

Androgen regulates SARS-CoV-2 receptor levels and is associated with severe COVID-19 symptoms in men 36 1

De novo design of ACE2 protein decoys to neutralize SARS-CoV-2 36 1

Possible transmission flow of SARS-CoV-2 based on ACE2 features 36 1

Impact of Comorbidities on SARS-CoV-2 Viral Entry-Related Genes 36 1

Potential microenvironment of SARS-CoV-2 infection in airway epithelial cells revealed by Human Protein Atlas database analysis 36 1

Interferons and viruses induce a novel primate-specific isoform dACE2 and not the SARS-CoV-2 receptor ACE2 36 1

A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability 36 24 1

Ceftazidime Is a Potential Drug to Inhibit SARS-CoV-2 Infection In Vitro by Blocking Spike Protein-ACE2 Interaction 36 1

Host range projection of SARS-CoV-2: South Asia perspective 36 1

SARS-CoV-2 Infection and Transmission Depends on Heparan Sulfates and Is Blocked by Low Molecular Weight Heparins 36 1

Functional and Genetic Analysis of Viral Receptor ACE2 Orthologs Reveals a Broad Potential Host Range of SARS-CoV-2 36 1

Structural basis for the recognition of the 2019-nCoV by human ACE2 36 1

Which animals are at risk? Predicting species susceptibility to Covid-19 36 1

Transferrin receptor is another receptor for SARS-CoV-2 entry 36 1

The D614G mutation of SARS-CoV-2 spike protein enhances viral infectivity 36 1

Does the human placenta express the canonical cell entry mediators for SARS-CoV-2? 36 1

Detection of Viral RNA Fragments in Human iPSC-Cardiomyocytes following Treatment with Extracellular Vesicles from SARS-CoV-2 Coding-Sequence-Overexpressing Lung Epithelial Cells 36 1

scRNA-seq reveals ACE2 and TMPRSS2 expression in TROP2+ Liver Progenitor Cells: Implications in COVID-19 associated Liver Dysfunction 36 1

Computational simulations reveal the binding dynamics between human ACE2 and the receptor binding domain of SARS-CoV-2 spike protein 36 1

An engineered stable mini-protein to plug SARS-Cov2 Spikes 36 1

Decrease in ACE2 mRNA expression in aged mouse lung 36 1

Ambroxol Hydrochloride Inhibits the Interaction between Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein's Receptor Binding Domain and Recombinant Human ACE2. 36 1

Strong evolutionary convergence of receptor-binding protein spike between COVID-19 and SARS-related coronaviruses 36 1

Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis 36 24 1

Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodies. 36 1

ACE2 fragment as a decoy for novel SARS-Cov-2 virus 36 1

Prefusion spike protein stabilization through computational mutagenesis 36 1

Cell-Type-Specific Expression of Renin-Angiotensin-System Components in the Human Body and Its Relevance to SARS-CoV-2 Infection 36 1

Neuropilin-1 facilitates SARS-CoV-2 cell entry and provides a possible pathway into the central nervous system 36 1

Monoclonal Antibodies Capable of Binding SARS-CoV-2 Spike Protein Receptor Binding Motif Specifically Prevent GM-CSF Induction. 36 1

Cyclooxgenase-2 is induced by SARS-CoV-2 infection but does not affect viral entry or replication 36 1

Obesity alters Ace2 and Tmprss2 expression in lung, trachea, and esophagus in a sex-dependent manner: Implications for COVID-19 36 1

S494 O-glycosylation site on the SARS-COV-2 RBD Affects the Virus Affinity to ACE2 and its Infectivity; A Molecular Dynamics Study 36 1

A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection 36 1

The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection 36 1

Angiotensin-converting enzyme 2 (ACE2) is upregulated in Alzheimers disease brain 36 1

Coronacept - a potent immunoadhesin against SARS-CoV-2 36 1

hACE2 peptide mimics block SARS-CoV-2 Pulmonary Cells Infection 36 1

Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling 36 1

Interaction of the spike protein RBD from SARS-CoV-2 with ACE2: similarity with SARS-CoV, hot-spot analysis and effect of the receptor polymorphism 36 1

A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent in vitro 36 1

SARS-CoV-2 receptor and entry genes are expressed by sustentacular cells in the human olfactory neuroepithelium 36 1

A simple protein-based surrogate neutralization assay for SARS-CoV-2 36 24 1

Comparison of Transgenic and Adenovirus hACE2 Mouse Models for SARS-CoV-2 Infection 36 1

The protein expression profile of ACE2 in human tissues 36 1

Angiotensin converting enzyme 2 is a novel target of the γ-secretase complex 36 1

The Pathogenicity of SARS-CoV-2 in hACE2 Transgenic Mice 36 1

Potential host range of multiple SARS-like coronaviruses and an improved ACE2-Fc variant that is potent against both SARS-CoV-2 and SARS-CoV-1 36 1

TRIM28 regulates SARS-CoV-2 cell entry by targeting ACE2 36 1

Evolutionary arms race between virus and host drives genetic diversity in bat SARS related coronavirus spike genes 36 1

Molecular mechanism of evolution and human infection with the novel coronavirus (2019-nCoV) 36 1

SARS-CoV-2 spike protein-mediated cell signaling in lung vascular cells 36 1

CD209L/L-SIGN and CD209/DC-SIGN act as receptors for SARS-CoV-2 and are differentially expressed in lung and kidney epithelial and endothelial cells 36 1

Dynamics of the ACE2 - SARS-CoV/SARS-CoV-2 spike protein interface reveal unique mechanisms 36 1

ACE2 Homo-dimerization, Human Genomic variants and Interaction of Host Proteins Explain High Population Specific Differences in Outcomes of COVID19 36 1

Meta-analysis of transcriptomes of SARS-Cov2 infected human lung epithelial cells identifies transmembrane serine proteases co-expressed with ACE2 and biological processes related to viral entry, immunity, inflammation and cellular stress. 36 1

mRNA induced expression of human angiotensin-converting enzyme 2 in mice for the study of the adaptive immune response to severe acute respiratory syndrome coronavirus 2 191 36 24 1

Distinct mechanisms for TMPRSS2 expression explain organ-specific inhibition of SARS-CoV-2 infection by enzalutamide 73 36 1

CD147 (BSG) but not ACE2 expression is detectable in vascular endothelial cells within single cell RNA sequencing datasets derived from multiple tissues in healthy individuals 36 1

Structure, Dynamics, Receptor Binding, and Antibody Binding of Fully-glycosylated Full-length SARS-CoV-2 Spike Protein in a Viral Membrane 36 1

Mutations from bat ACE2 orthologs markedly enhance ACE2-Fc neutralization of SARS-CoV-2 36 1

Expression of ACE2 and TMPRSS2 proteins in the upper and lower aerodigestive tracts of rats 36 1

Alpha 1 Antitrypsin is an Inhibitor of the SARS-CoV-2-Priming Protease TMPRSS2 36 1

High affinity binding of SARS-CoV-2 spike protein enhances ACE2 carboxypeptidase activity 36 1

Regulation of angiotensin converting enzyme 2 (ACE2) in obesity: implications for COVID-19 36 1

Elucidating the differences in the molecular mechanism of receptor binding between 2019-nCoV and the SARS-CoV viruses using computational tools 36 1

On the interactions of the receptor-binding domain of SARS-CoV-1 and SARS-CoV-2 spike proteins with monoclonal antibodies and the receptor ACE2 36 1

Rapid Development of Neutralizing and Diagnostic SARS-COV-2 Mouse Monoclonal Antibodies 24 1

Angiotensin-converting enzyme 2, a SARS-CoV-2 receptor, is upregulated by interleukin-6 via STAT3 signaling in rheumatoid synovium 36 1

Single-cell RNA expression profiling of ACE2,thereceptor of SARS-CoV-2 36 1

Targeting ACE2-RBD interaction as a platform for COVID19 therapeutics: Development and drug repurposing screen of an AlphaLISA proximity assay 36 1

ACE2-Variants Indicate Potential SARS-CoV-2-Susceptibility in Animals: An Extensive Molecular Dynamics Study 36 1

Critical Interactions Between the SARS-CoV-2 Spike Glycoprotein and the Human ACE2 Receptor 36 1

Neutralizing Antibodies Isolated by a site-directed Screening have Potent Protection on SARS-CoV-2 Infection 24 1

The discovery of potential natural products for targeting SARS-CoV-2 spike protein by virtual screening 36 1

Significant expression of FURIN and ACE2 on oral epithelial cells may facilitate the efficiency of SARS-CoV-2 entry 36 1

SARS-CoV-2 Productively Infects Human Gut Enterocytes 36 1

High expression of angiotensin-converting enzyme-2 (ACE2) on tissue macrophages that may be targeted by virus SARS-CoV-2 in COVID-19 patients 36 1

Comprehensive characterization of N- and O- glycosylation of SARS-CoV-2 human receptor angiotensin converting enzyme 2. 36 1

Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon 36 1

Beyond Shielding: The Roles of Glycans in SARS-CoV-2 Spike Protein 36 1

Biomechanical Characterization of SARS-CoV-2 Spike RBD and Human ACE2 Protein-Protein Interaction 36 1

Trimeric SARS-CoV-2 Spike interacts with dimeric ACE2 with limited intra-Spike avidity 36 24 1

Potent human neutralizing antibodies elicited by SARS-CoV-2 infection 24 1

Synthetic antibodies neutralize SARS-CoV-2 infection of mammalian cells 103 36 1